Proteins > Poly [ADP-ribose] polymerase 2
Page last updated: 2024-08-08 00:21:33
Poly [ADP-ribose] polymerase 2
A poly [ADP-ribose] polymerase 2 that is encoded in the genome of human. [PRO:DNx]
Synonyms
PARP-2;
hPARP-2;
EC 2.4.2.30;
ADP-ribosyltransferase diphtheria toxin-like 2;
ARTD2;
DNA ADP-ribosyltransferase PARP2;
2.4.2.-;
NAD(+) ADP-ribosyltransferase 2;
ADPRT-2;
Poly[ADP-ribose] synthase 2;
pADPRT-2;
P
Research
Bioassay Publications (43)
Timeframe | Studies on this Protein(%) | All Drugs % |
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (6.98) | 29.6817 |
2010's | 24 (55.81) | 24.3611 |
2020's | 16 (37.21) | 2.80 |
Compounds (14)
Drugs with Inhibition Measurements
Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
pj-34 | Homo sapiens (human) | IC50 | 0.1687 | 3 | 5 |
4-Methoxybenzamide | Homo sapiens (human) | IC50 | 77.0000 | 1 | 1 |
amentoflavone | Homo sapiens (human) | IC50 | 10.3000 | 2 | 2 |
rucaparib | Homo sapiens (human) | IC50 | 0.0497 | 9 | 11 |
rucaparib | Homo sapiens (human) | Ki | 0.0007 | 1 | 1 |
veliparib | Homo sapiens (human) | IC50 | 0.0688 | 7 | 9 |
veliparib | Homo sapiens (human) | Ki | 0.0113 | 2 | 2 |
olaparib | Homo sapiens (human) | IC50 | 0.1866 | 22 | 24 |
niraparib | Homo sapiens (human) | IC50 | 0.2306 | 7 | 8 |
niraparib | Homo sapiens (human) | Ki | 0.0040 | 1 | 1 |
iwr-1 endo | Homo sapiens (human) | IC50 | 53.4900 | 5 | 5 |
nms-p118 | Homo sapiens (human) | IC50 | 6.6000 | 1 | 1 |
g007-lk | Homo sapiens (human) | IC50 | 100.0000 | 2 | 2 |
xav939 | Homo sapiens (human) | IC50 | 0.5276 | 10 | 11 |
bmn 673 | Homo sapiens (human) | IC50 | 0.0079 | 4 | 4 |
bmn 673 | Homo sapiens (human) | Ki | 0.0009 | 2 | 2 |
nvp-tnks656 | Homo sapiens (human) | IC50 | 32.0000 | 1 | 1 |
Drugs with Activation Measurements
Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
rucaparib | Homo sapiens (human) | EC50 | 0.0047 | 1 | 1 |
rucaparib | Homo sapiens (human) | Kd | 0.0260 | 1 | 1 |
veliparib | Homo sapiens (human) | EC50 | 0.0059 | 1 | 1 |
veliparib | Homo sapiens (human) | Kd | 0.0084 | 2 | 2 |
olaparib | Homo sapiens (human) | EC50 | 0.0036 | 1 | 1 |
olaparib | Homo sapiens (human) | Kd | 0.0004 | 3 | 3 |
niraparib | Homo sapiens (human) | EC50 | 0.0240 | 2 | 2 |
niraparib | Homo sapiens (human) | EC50 | 0.0040 | 2 | 2 |
niraparib | Homo sapiens (human) | Kd | 0.0780 | 1 | 1 |
nms-p118 | Homo sapiens (human) | Kd | 1.3945 | 2 | 2 |
bmn 673 | Homo sapiens (human) | EC50 | 0.0025 | 2 | 2 |
bmn 673 | Homo sapiens (human) | Kd | 0.0033 | 1 | 1 |
Drugs with Other Measurements
Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
niraparib | Homo sapiens (human) | EC90 | 0.2200 | 1 | 1 |
niraparib | Homo sapiens (human) | EC90 | 0.0450 | 1 | 1 |
niraparib | Homo sapiens (human) | IC90 | 0.0493 | 3 | 3 |
From PARP1 to TNKS2 Inhibition: A Structure-Based Approach.ACS medicinal chemistry letters, , May-14, Volume: 11, Issue:5, 2020
Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors.Journal of medicinal chemistry, , 02-23, Volume: 60, Issue:4, 2017
Discovery of 4-Hydroxyquinazoline Derivatives as Small Molecular BET/PARP1 Inhibitors That Induce Defective Homologous Recombination and Lead to Synthetic Lethality for Triple-Negative Breast Cancer Therapy.Journal of medicinal chemistry, , 05-12, Volume: 65, Issue:9, 2022
Structure-based design, synthesis, and evaluation of inhibitors with high selectivity for PARP-1 over PARP-2.European journal of medicinal chemistry, , Jan-05, Volume: 227, 2022
Recent advances in DDR (DNA damage response) inhibitors for cancer therapy.European journal of medicinal chemistry, , Feb-15, Volume: 230, 2022
Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-Journal of medicinal chemistry, , 10-14, Volume: 64, Issue:19, 2021
Small-molecule inhibitors of breast cancer-related targets: Potential therapeutic agents for breast cancer.European journal of medicinal chemistry, , Jan-15, Volume: 210, 2021
Discovery of isoquinolinone and naphthyridinone-based inhibitors of poly(ADP-ribose) polymerase-1 (PARP1) as anticancer agents: Structure activity relationship and preclinical characterization.Bioorganic & medicinal chemistry, , 12-15, Volume: 28, Issue:24, 2020
[no title available]Journal of medicinal chemistry, , 06-13, Volume: 62, Issue:11, 2019
Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors.Journal of medicinal chemistry, , 02-23, Volume: 60, Issue:4, 2017
Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) PolymerJournal of medicinal chemistry, , Jan-14, Volume: 59, Issue:1, 2016
Recent advances in DDR (DNA damage response) inhibitors for cancer therapy.European journal of medicinal chemistry, , Feb-15, Volume: 230, 2022
Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-Journal of medicinal chemistry, , 10-14, Volume: 64, Issue:19, 2021
[no title available]Journal of medicinal chemistry, , 06-13, Volume: 62, Issue:11, 2019
Design and synthesis of 2-(4,5,6,7-tetrahydrothienopyridin-2-yl)-benzoimidazole carboxamides as novel orally efficacious Poly(ADP-ribose)polymerase (PARP) inhibitors.European journal of medicinal chemistry, , Feb-10, Volume: 145, 2018
Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors.Journal of medicinal chemistry, , 02-23, Volume: 60, Issue:4, 2017
Novel tricyclic poly (ADP-ribose) polymerase-1/2 inhibitors with potent anticancer chemopotentiating activity: Design, synthesis and biological evaluation.Bioorganic & medicinal chemistry, , 10-01, Volume: 24, Issue:19, 2016
Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) PolymerJournal of medicinal chemistry, , Jan-14, Volume: 59, Issue:1, 2016
Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy.Journal of medicinal chemistry, , Sep-10, Volume: 58, Issue:17, 2015
Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer.Journal of medicinal chemistry, , Jan-22, Volume: 52, Issue:2, 2009
Synthesis and in vitro biological evaluation of 3-ethyl-1,5-naphthyridin-2(1H)-one derivatives as potent PARP-1 selective inhibitors and PARP-1 DNA trappers.Bioorganic & medicinal chemistry letters, , 12-15, Volume: 78, 2022
Selective degradation of PARP2 by PROTACs via recruiting DCAF16 for triple-negative breast cancer.European journal of medicinal chemistry, , Jun-05, Volume: 236, 2022
Recent advances in DDR (DNA damage response) inhibitors for cancer therapy.European journal of medicinal chemistry, , Feb-15, Volume: 230, 2022
Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-Journal of medicinal chemistry, , 10-14, Volume: 64, Issue:19, 2021
[no title available]Journal of medicinal chemistry, , 11-25, Volume: 64, Issue:22, 2021
Identification of 2-substituted pyrrolo[1,2-b]pyridazine derivatives as new PARP-1 inhibitors.Bioorganic & medicinal chemistry letters, , 01-01, Volume: 31, 2021
[no title available]Journal of medicinal chemistry, , 08-26, Volume: 64, Issue:16, 2021
Discovery of isoquinolinone and naphthyridinone-based inhibitors of poly(ADP-ribose) polymerase-1 (PARP1) as anticancer agents: Structure activity relationship and preclinical characterization.Bioorganic & medicinal chemistry, , 12-15, Volume: 28, Issue:24, 2020
Discovery of Pamiparib (BGB-290), a Potent and Selective Poly (ADP-ribose) Polymerase (PARP) Inhibitor in Clinical Development.Journal of medicinal chemistry, , 12-24, Volume: 63, Issue:24, 2020
[no title available]Journal of medicinal chemistry, , 01-09, Volume: 63, Issue:1, 2020
Discovery of Novel Bromophenol-Thiosemicarbazone Hybrids as Potent Selective Inhibitors of Poly(ADP-ribose) Polymerase-1 (PARP-1) for Use in Cancer.Journal of medicinal chemistry, , 03-28, Volume: 62, Issue:6, 2019
Synthesis and biological activity of structurally diverse phthalazine derivatives: A systematic review.Bioorganic & medicinal chemistry, , 09-15, Volume: 27, Issue:18, 2019
[no title available]Journal of medicinal chemistry, , 06-13, Volume: 62, Issue:11, 2019
Design and synthesis of 2-(4,5,6,7-tetrahydrothienopyridin-2-yl)-benzoimidazole carboxamides as novel orally efficacious Poly(ADP-ribose)polymerase (PARP) inhibitors.European journal of medicinal chemistry, , Feb-10, Volume: 145, 2018
Olaparib hydroxamic acid derivatives as dual PARP and HDAC inhibitors for cancer therapy.Bioorganic & medicinal chemistry, , 08-01, Volume: 25, Issue:15, 2017
Discovery of novel quinazoline-2,4(1H,3H)-dione derivatives as potent PARP-2 selective inhibitors.Bioorganic & medicinal chemistry, , 08-01, Volume: 25, Issue:15, 2017
Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors.Journal of medicinal chemistry, , 02-23, Volume: 60, Issue:4, 2017
Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) PolymerJournal of medicinal chemistry, , Jan-14, Volume: 59, Issue:1, 2016
Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy.Journal of medicinal chemistry, , Sep-10, Volume: 58, Issue:17, 2015
Discovery of AZ0108, an orally bioavailable phthalazinone PARP inhibitor that blocks centrosome clustering.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 25, Issue:24, 2015
Design, synthesis, and biological evaluation of a series of benzo[de][1,7]naphthyridin-7(8H)-ones bearing a functionalized longer chain appendage as novel PARP1 inhibitors.Journal of medicinal chemistry, , Apr-11, Volume: 56, Issue:7, 2013
4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1.Journal of medicinal chemistry, , Oct-23, Volume: 51, Issue:20, 2008
Niraparib: A Poly(ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination.Journal of medicinal chemistry, , Apr-23, Volume: 58, Issue:8, 2015
Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors.Journal of medicinal chemistry, , Nov-26, Volume: 52, Issue:22, 2009
Recent advances in DDR (DNA damage response) inhibitors for cancer therapy.European journal of medicinal chemistry, , Feb-15, Volume: 230, 2022
Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-Journal of medicinal chemistry, , 10-14, Volume: 64, Issue:19, 2021
Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents - A recent update.European journal of medicinal chemistry, , Mar-01, Volume: 165, 2019
Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors.Journal of medicinal chemistry, , 02-23, Volume: 60, Issue:4, 2017
Niraparib: A Poly(ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination.Journal of medicinal chemistry, , Apr-23, Volume: 58, Issue:8, 2015
Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors.Journal of medicinal chemistry, , Nov-26, Volume: 52, Issue:22, 2009
Small-Molecule Inhibitors of Tankyrases as Prospective Therapeutics for Cancer.Journal of medicinal chemistry, , 04-14, Volume: 65, Issue:7, 2022
Discovery of novel, induced-pocket binding oxazolidinones as potent, selective, and orally bioavailable tankyrase inhibitors.Journal of medicinal chemistry, , Jun-13, Volume: 56, Issue:11, 2013
Discovery of a class of novel tankyrase inhibitors that bind to both the nicotinamide pocket and the induced pocket.Journal of medicinal chemistry, , Feb-14, Volume: 56, Issue:3, 2013
Structural basis of selective inhibition of human tankyrases.Journal of medicinal chemistry, , Feb-09, Volume: 55, Issue:3, 2012
Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-Journal of medicinal chemistry, , 10-14, Volume: 64, Issue:19, 2021
[no title available]Journal of medicinal chemistry, , 08-26, Volume: 64, Issue:16, 2021
Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy.Journal of medicinal chemistry, , Sep-10, Volume: 58, Issue:17, 2015
Design and Discovery of an Orally Efficacious Spiroindolinone-Based Tankyrase Inhibitor for the Treatment of Colon Cancer.Journal of medicinal chemistry, , 04-23, Volume: 63, Issue:8, 2020
Discovery of Novel Spiroindoline Derivatives as Selective Tankyrase Inhibitors.Journal of medicinal chemistry, , 04-11, Volume: 62, Issue:7, 2019
Small-Molecule Inhibitors of Tankyrases as Prospective Therapeutics for Cancer.Journal of medicinal chemistry, , 04-14, Volume: 65, Issue:7, 2022
Discovery of a Highly Selective Tankyrase Inhibitor Displaying Growth Inhibition Effects against a Diverse Range of Tumor Derived Cell Lines.Journal of medicinal chemistry, , 07-13, Volume: 60, Issue:13, 2017
Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors.Journal of medicinal chemistry, , 02-23, Volume: 60, Issue:4, 2017
Fragment-based ligand design of novel potent inhibitors of tankyrases.Journal of medicinal chemistry, , Jun-13, Volume: 56, Issue:11, 2013
Structure-efficiency relationship of [1,2,4]triazol-3-ylamines as novel nicotinamide isosteres that inhibit tankyrases.Journal of medicinal chemistry, , Sep-12, Volume: 56, Issue:17, 2013
Identification of NVP-TNKS656: the use of structure-efficiency relationships to generate a highly potent, selective, and orally active tankyrase inhibitor.Journal of medicinal chemistry, , Aug-22, Volume: 56, Issue:16, 2013
Discovery of a class of novel tankyrase inhibitors that bind to both the nicotinamide pocket and the induced pocket.Journal of medicinal chemistry, , Feb-14, Volume: 56, Issue:3, 2013
[1,2,4]triazol-3-ylsulfanylmethyl)-3-phenyl-[1,2,4]oxadiazoles: antagonists of the Wnt pathway that inhibit tankyrases 1 and 2 via novel adenosine pocket binding.Journal of medicinal chemistry, , Feb-09, Volume: 55, Issue:3, 2012
Structural basis of selective inhibition of human tankyrases.Journal of medicinal chemistry, , Feb-09, Volume: 55, Issue:3, 2012
Discovery of 4-Hydroxyquinazoline Derivatives as Small Molecular BET/PARP1 Inhibitors That Induce Defective Homologous Recombination and Lead to Synthetic Lethality for Triple-Negative Breast Cancer Therapy.Journal of medicinal chemistry, , 05-12, Volume: 65, Issue:9, 2022
Recent advances in DDR (DNA damage response) inhibitors for cancer therapy.European journal of medicinal chemistry, , Feb-15, Volume: 230, 2022
Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-Journal of medicinal chemistry, , 10-14, Volume: 64, Issue:19, 2021
Discovery of isoquinolinone and naphthyridinone-based inhibitors of poly(ADP-ribose) polymerase-1 (PARP1) as anticancer agents: Structure activity relationship and preclinical characterization.Bioorganic & medicinal chemistry, , 12-15, Volume: 28, Issue:24, 2020
Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents - A recent update.European journal of medicinal chemistry, , Mar-01, Volume: 165, 2019
Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) PolymerJournal of medicinal chemistry, , Jan-14, Volume: 59, Issue:1, 2016
Niraparib: A Poly(ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination.Journal of medicinal chemistry, , Apr-23, Volume: 58, Issue:8, 2015
Enables
This protein enables 13 target(s):
Target | Category | Definition |
chromatin binding | molecular function | Binding to chromatin, the network of fibers of DNA, protein, and sometimes RNA, that make up the chromosomes of the eukaryotic nucleus during interphase. [GOC:jl, ISBN:0198506732, PMID:20404130] |
damaged DNA binding | molecular function | Binding to damaged DNA. [GOC:jl] |
NAD+ ADP-ribosyltransferase activity | molecular function | Catalysis of the reaction: NAD+ + (ADP-D-ribosyl)(n)-acceptor = nicotinamide + (ADP-D-ribosyl)(n+1)-acceptor. [EC:2.4.2.30] |
protein binding | molecular function | Binding to a protein. [GOC:go_curators] |
nucleotidyltransferase activity | molecular function | Catalysis of the transfer of a nucleotidyl group to a reactant. [ISBN:0198506732] |
nucleosome binding | molecular function | Binding to a nucleosome, a complex comprised of DNA wound around a multisubunit core and associated proteins, which forms the primary packing unit of DNA into higher order structures. [GOC:mah] |
poly-ADP-D-ribose binding | molecular function | Binding to polymeric ADP-D-ribose, a polymer that is composed of poly-ADP-D-ribose units linked through 1,2-glycosidic bonds at the ribose ring. [GOC:mah, GOC:sart, PMID:20088964] |
NAD DNA ADP-ribosyltransferase activity | molecular function | Catalysis of the transfer of the ADP-ribose group of NAD+ to a residue in double-stranded DNA. [PMID:27471034, PMID:29361132, PMID:29520010] |
NAD+-protein-serine ADP-ribosyltransferase activity | molecular function | Catalysis of the reaction: L-seryl-[protein] + NAD+ = H+ + nicotinamide + O-(ADP-D-ribosyl)-L-seryl-[protein]. [PMID:32028527, PMID:33186521, RHEA:58232] |
NAD+- protein-aspartate ADP-ribosyltransferase activity | molecular function | Catalysis of the reaction: L-aspartyl-[protein] + NAD+ = 4-O-(ADP-D-ribosyl)-L-aspartyl-[protein] + nicotinamide. [PMID:19764761, PMID:25043379, RHEA:54424] |
NAD+-protein-glutamate ADP-ribosyltransferase activity | molecular function | Catalysis of the reaction: L-glutamyl-[protein] + NAD+ = 5-O-(ADP-D-ribosyl)-L-glutamyl-[protein] + nicotinamide. [PMID:19764761, PMID:25043379, RHEA:58224] |
poly-ADP-D-ribose modification-dependent protein binding | molecular function | Binding to a protein upon poly-ADP-ribosylation of the target protein. [PMID:26673700] |
NAD+-protein ADP-ribosyltransferase activity | molecular function | Catalysis of the reaction: amino acyl-[protein] + NAD+ = H+ + (ADP-D-ribosyl)-amino acyl-[protein] + nicotinamide. [PMID:1899243] |
Located In
This protein is located in 4 target(s):
Target | Category | Definition |
nucleus | cellular component | A membrane-bounded organelle of eukaryotic cells in which chromosomes are housed and replicated. In most cells, the nucleus contains all of the cell's chromosomes except the organellar chromosomes, and is the site of RNA synthesis and processing. In some species, or in specialized cell types, RNA metabolism or DNA replication may be absent. [GOC:go_curators] |
nucleoplasm | cellular component | That part of the nuclear content other than the chromosomes or the nucleolus. [GOC:ma, ISBN:0124325653] |
nucleolus | cellular component | A small, dense body one or more of which are present in the nucleus of eukaryotic cells. It is rich in RNA and protein, is not bounded by a limiting membrane, and is not seen during mitosis. Its prime function is the transcription of the nucleolar DNA into 45S ribosomal-precursor RNA, the processing of this RNA into 5.8S, 18S, and 28S components of ribosomal RNA, and the association of these components with 5S RNA and proteins synthesized outside the nucleolus. This association results in the formation of ribonucleoprotein precursors; these pass into the cytoplasm and mature into the 40S and 60S subunits of the ribosome. [ISBN:0198506732] |
site of DNA damage | cellular component | A region of a chromosome at which DNA damage has occurred. DNA damage signaling and repair proteins accumulate at the lesion to respond to the damage and repair the DNA to form a continuous DNA helix. [GOC:pg] |
Active In
This protein is active in 2 target(s):
Target | Category | Definition |
site of DNA damage | cellular component | A region of a chromosome at which DNA damage has occurred. DNA damage signaling and repair proteins accumulate at the lesion to respond to the damage and repair the DNA to form a continuous DNA helix. [GOC:pg] |
nucleolus | cellular component | A small, dense body one or more of which are present in the nucleus of eukaryotic cells. It is rich in RNA and protein, is not bounded by a limiting membrane, and is not seen during mitosis. Its prime function is the transcription of the nucleolar DNA into 45S ribosomal-precursor RNA, the processing of this RNA into 5.8S, 18S, and 28S components of ribosomal RNA, and the association of these components with 5S RNA and proteins synthesized outside the nucleolus. This association results in the formation of ribonucleoprotein precursors; these pass into the cytoplasm and mature into the 40S and 60S subunits of the ribosome. [ISBN:0198506732] |
Involved In
This protein is involved in 13 target(s):
Target | Category | Definition |
DNA repair | biological process | The process of restoring DNA after damage. Genomes are subject to damage by chemical and physical agents in the environment (e.g. UV and ionizing radiations, chemical mutagens, fungal and bacterial toxins, etc.) and by free radicals or alkylating agents endogenously generated in metabolism. DNA is also damaged because of errors during its replication. A variety of different DNA repair pathways have been reported that include direct reversal, base excision repair, nucleotide excision repair, photoreactivation, bypass, double-strand break repair pathway, and mismatch repair pathway. [PMID:11563486] |
base-excision repair | biological process | In base excision repair, an altered base is removed by a DNA glycosylase enzyme, followed by excision of the resulting sugar phosphate. The small gap left in the DNA helix is filled in by the sequential action of DNA polymerase and DNA ligase. [ISBN:0815316194] |
DNA damage response | biological process | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus indicating damage to its DNA from environmental insults or errors during metabolism. [GOC:go_curators] |
DNA ADP-ribosylation | biological process | The covalent attachment of an ADP-ribosyl group to a residue in double-stranded DNA. [PMID:11592983, PMID:27471034, PMID:29361132, PMID:29520010] |
decidualization | biological process | The cellular and vascular changes occurring in the endometrium of the pregnant uterus just after the onset of blastocyst implantation. This process involves the proliferation and differentiation of the fibroblast-like endometrial stromal cells into large, polyploid decidual cells that eventually form the maternal component of the placenta. [ISBN:0721662544, PMID:11133685] |
positive regulation of cell growth involved in cardiac muscle cell development | biological process | Any process that increases the rate, frequency, or extent of the growth of a cardiac muscle cell, where growth contributes to the progression of the cell over time from its initial formation to its mature state. [GOC:dph] |
protein poly-ADP-ribosylation | biological process | The transfer of multiple ADP-ribose residues from NAD to a protein amino acid, forming a poly(ADP-ribose) chain. [GOC:BHF, GOC:mah, GOC:rl, PMID:25043379] |
protein auto-ADP-ribosylation | biological process | The ADP-ribosylation by a protein of one or more of its own amino acid residues, or residues on an identical protein. [GOC:BHF, GOC:rl] |
response to oxygen-glucose deprivation | biological process | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of the deprivation of oxygen and glucose. [GOC:sl, PMID:21525936] |
extrinsic apoptotic signaling pathway | biological process | The series of molecular signals in which a signal is conveyed from the cell surface to trigger the apoptotic death of a cell. The pathway starts with either a ligand binding to a cell surface receptor, or a ligand being withdrawn from a cell surface receptor (e.g. in the case of signaling by dependence receptors), and ends when the execution phase of apoptosis is triggered. [GOC:mtg_apoptosis, GOC:yaf, PMID:17340152] |
hippocampal neuron apoptotic process | biological process | Any apoptotic process that occurs in a hippocampal neuron. [GOC:sl, PMID:18940801] |
DNA repair-dependent chromatin remodeling | biological process | A chromatin remodeling process that allows DNA repair enzyme to access genomic DNA and repair DNA lesions. [PMID:15528408, PMID:28053344, PMID:29095668, PMID:35689883] |
double-strand break repair | biological process | The repair of double-strand breaks in DNA via homologous and nonhomologous mechanisms to reform a continuous DNA helix. [GOC:elh] |